The interaction of core modules as a basis for elucidating network behavior determining Parkinson's disease pathogenesis.
作者信息
Menon Govind, Bakshi Suruchi, Krishnan J
机构信息
Department of Chemical Engineering, Sargent Centre for Process Systems Engineering, Imperial College London, London, UK.
Certara QSP, Breda, The Netherlands.
出版信息
CPT Pharmacometrics Syst Pharmacol. 2024 Mar;13(3):335-340. doi: 10.1002/psp4.13108. Epub 2024 Feb 9.
Abstract
摘要
相似文献
1
The interaction of core modules as a basis for elucidating network behavior determining Parkinson's disease pathogenesis.
CPT Pharmacometrics Syst Pharmacol. 2024 Mar;13(3):335-340. doi: 10.1002/psp4.13108. Epub 2024 Feb 9.
2
Expression characteristics of peripheral blood genes reveal potential biomarkers and candidate therapeutic targets for Parkinson's disease.
Cell Mol Biol (Noisy-le-grand). 2020 May 15;66(2):118-124.
3
MiRNAs participate in the diagnosis, pathogenesis and therapy of Parkinson's disease.
Histol Histopathol. 2018 May;33(5):447-453. doi: 10.14670/HH-11-944. Epub 2017 Nov 14.
4
MicroRNAs: possible role in pathogenesis of Parkinson's disease.
Biochemistry (Mosc). 2012 Aug;77(8):813-9. doi: 10.1134/S0006297912080020.
5
Common gene expression signatures in Parkinson's disease are driven by changes in cell composition.
Acta Neuropathol Commun. 2020 Apr 21;8(1):55. doi: 10.1186/s40478-020-00932-7.
6
Construction of Parkinson's disease marker-based weighted protein-protein interaction network for prioritization of co-expressed genes.
Gene. 2019 May 20;697:67-77. doi: 10.1016/j.gene.2019.02.026. Epub 2019 Feb 16.
7
Oxidative stress in genetic mouse models of Parkinson's disease.
Oxid Med Cell Longev. 2012;2012:624925. doi: 10.1155/2012/624925. Epub 2012 Jul 8.
8
Regional transcriptional architecture of Parkinson's disease pathogenesis and network spread.
Brain. 2019 Oct 1;142(10):3072-3085. doi: 10.1093/brain/awz223.
9
Heritability Enrichment Implicates Microglia in Parkinson's Disease Pathogenesis.
Ann Neurol. 2021 May;89(5):942-951. doi: 10.1002/ana.26032. Epub 2021 Mar 4.
10
Network Analysis Identifies Disease-Specific Pathways for Parkinson's Disease.
Mol Neurobiol. 2018 Jan;55(1):370-381. doi: 10.1007/s12035-016-0326-0. Epub 2016 Dec 21.
引用本文的文献
1
A mechanistic model of pure and lipidic α-synuclein aggregation for advancing Parkinson's therapies.
Commun Chem. 2025 Jun 14;8(1):186. doi: 10.1038/s42004-025-01558-3.
本文引用的文献
1
The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings.
Mov Disord. 2021 Apr;36(4):1005-1010. doi: 10.1002/mds.28416. Epub 2020 Dec 14.
2
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020.
J Parkinsons Dis. 2020;10(3):757-774. doi: 10.3233/JPD-202128.
3
Mathematical Biology Models of Parkinson's Disease.
CPT Pharmacometrics Syst Pharmacol. 2019 Feb;8(2):77-86. doi: 10.1002/psp4.12362. Epub 2018 Nov 2.
4
Parkinson disease.
Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13.
5
Bridging the gap between modules in isolation and as part of networks: A systems framework for elucidating interaction and regulation of signalling modules.
J Chem Phys. 2016 Jul 21;145(3):035103. doi: 10.1063/1.4953914.
6
Parkinson's disease.
Lancet. 2015 Aug 29;386(9996):896-912. doi: 10.1016/S0140-6736(14)61393-3. Epub 2015 Apr 19.
7
Feedback motif for the pathogenesis of Parkinson's disease.
IET Syst Biol. 2012 Jun;6(3):86-93. doi: 10.1049/iet-syb.2011.0076.
8
Modeling proteasome dynamics in Parkinson's disease.
Phys Biol. 2009 May 1;6(3):036005. doi: 10.1088/1478-3975/6/3/036005.
9
Levodopa and the progression of Parkinson's disease.
N Engl J Med. 2004 Dec 9;351(24):2498-508. doi: 10.1056/NEJMoa033447.
Zotero 插件